Pfizer Halts Cholsterol-Drug Trial
Pfizer (PFE) stopped all torcetrapib (cholesterol drug) trials following the Data Safety Monitoring Board's recommendation that Pfizer terminate a study due to the imbalance of mortality and cardiovascular events. Sees 2007 and 2008 revenue similar to 2006.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.